Team

Talented laboratory scientists, medicinal chemists, and biotech leaders with successful track records in oncological drug development.

Science and Operations

  • Photo: Greg Crimmins

    Greg Crimmins

    Chief Executive Officer, Founder

    Ph. D.

    Greg has a Ph.D. in molecular biology from University of California, Berkeley, where he helped invent a promising new way to treat cancer with immunotherapy. He has 20 years of experience in biomedical research, including phenotypic screening, cell biology, and immunology. Greg has led Remedy Plan from inception through development of its drug screening platform to the optimization of novel first-in-class cancer therapeutics.

  • Photo: Dennise A. De Jesús-Díaz

    Dennise A. De Jesús-Díaz

    Chief Operations Officer

    Ph. D.

    Dennise provides project leadership for our scientific operations and is responsible for development and implementation of effective research practices. She has worked in biomedical research for over 10 years, most recently at the National Institutes of Health. She holds a B.S. from the University of Puerto Rico at Cayey and a Ph.D. from Tufts University School of Medicine.

  • Photo: Cassandra Choe-Juliak

    Cassandra Choe-Juliak

    Acting Chief Medical Officer

    M.D., M.S.

    Dr. Cassandra Choe-Juliak has 20 years of experience in drug development. She previously worked at Pfizer, Ipsen and Karyopharm Therapeutics where she led the initial success of Selinexor, a first-in-class XPO1 inhibitor in multiple myeloma. Cassandra has also supported programs for Affimed where she led the clinical department, and at Flame Bioscences where she acts as Chief Medical Officer.

  • Photo: Yushma Bhurruth-Alcor

    Yushma Bhurruth-Alcor

    Executive Director, Medicinal Chemistry

    Ph.D.

    Yushma brings extensive pharmaceutical drug discovery experience to the Remedy Plan team. She has worked for 10 years in the pharmaceutical industry for companies such as GlaxoSmithKline, Galderma-NSH, and Johnson & Johnson, where she successfully developed new clinical drug candidates. After graduating from the ESPCI in Paris, Yushma obtained her Ph.D. in Chemistry from Imperial College London.

  • Photo: Min Wu

    Min Wu

    Senior Scientist, Biology

    Ph.D.

    Min earned her M.S. in chemistry from University of Maryland at Baltimore County and her Ph.D. in molecular biology and genetics from Johns Hopkins University School of Medicine. She conducted postdoctoral research at Memorial Sloan Kettering Cancer Center on the crucial mechanisms of DNA replication and repair, and later at Johns Hopkins University School of Medicine on translational studies of acute myeloid leukemia with a focus on identifying novel therapeutic targets.

  • Photo: Tim Jarvela

    Tim Jarvela

    Senior Scientist, Biology

    Ph.D.

    Tim has a Ph.D. in biology from Carnegie Mellon University and performed his postdoctoral work at the University of Maryland School of Medicine in Baltimore. His research background is in the underlying cellular and molecular biology of proteins that maintain proper cell health. He has applied this to the study of diverse research topics such as diabetes and neurodegenerative diseases.

  • Photo: Caroline Robb

    Caroline Robb

    Senior Project Manager

    Ph.D.

    Caroline joins the Remedy Plan team with a strong background in oncology drug discovery. She received her Ph.D. in Cancer Research from the University of Nebraska Medical Center and conducted her postdoctoral research as a fellow at Memorial Sloan Kettering Cancer Center in NYC. Throughout her training, Caroline has focused on characterization of mechanisms of action and target identification studies to identify new cancer therapies.

  • Photo: Dexter Davis

    Dexter Davis

    Research Scientist II

    Ph.D.

    Dexter joins the Remedy Plan team with more than three years of experience in the pharmaceutical industry and a strong background in medicinal chemistry. He has successfully optimized and developed clinical drug candidates in the area of small molecule antivirals targeting hepatitis B and SARS-CoV-2. He received his Ph.D. in organic chemistry from Purdue University and carried out postdoctoral work at the Warren Center for Neuroscience Drug Discovery at Vanderbilt University.

  • Photo: Parisa Moghaddam-Taaheri

    Parisa Moghaddam-Taaheri

    Senior Business Development Manager

    Ph.D.

    Parisa joins the Remedy Plan team with an extensive background in biomedical research and healthcare and life sciences consulting. She received her Ph.D. in Bioengineering from the University of Maryland, College Park where her research focused on protein and peptide engineering for therapeutic applications. At Remedy Plan, she manages business development activities including external partnerships and strategic communications.

  • Photo: Frank Roushar

    Frank Roushar

    Research Scientist I

    Ph.D.

    Frank has a Ph.D. in Chemistry from Indiana University-Bloomington and performed his postdoctoral work at the NIH Clinical Center. His research background focuses on membrane protein folding and disease as well as cellular signaling. He has applied his skills to problems ranging from the underlying principles of membrane protein misfolding to developing approaches for precision medicine.

  • Photo: James Digel

    James Digel

    Research Technician I

    B.S.

    James received his B.S. in Biology from the University of Maryland, College Park, with a focus on evolutionary development and molecular biology. His past research includes risk assessment for using dsRNA in agricultural settings as a species-specific pesticide through RNA interference. At Remedy Plan, James supports mechanism of action and target engagement studies.

  • Photo: Claudia Fabiola Ramos

    Claudia Fabiola Ramos

    Research Assistant

    A.S.

    Fabie is currently pursuing a B.S. in Biological Science at the University of Maryland, College Park, with a focus on Physiology and Neurobiology, with a minor in Criminal Justice. At Remedy Plan, she supports compound management, inventory management, and laboratory operations.

  • Photo: Asra Rehan

    Asra Rehan

    Project Coordinator

    MBA

    Asra joins Remedy Plan with several years of experience in project management and professional services. She successfully led cross-functional teams and projects, ranging from product & development to sales & marketing, from launch to completion. She has built lasting relationships with long-term and high-profile clients resulting in higher customer retention and brand loyalty. Asra earned her B.S. in Biomedical Engineering from the Georgia Institute of Technology and her MBA from Emory University. With her background in the biomedical sciences and business degree and experience, Asra supports business development at Remedy Plan.

Scientific Advisory Board

  • Photo: Frank McCormick

    Frank McCormick

    Advisor

    Ph.D., FRS, DSc

    Frank is a Professor at the University of California San Francisco (UCSF) Comprehensive Cancer Center and founder of Onyx Pharmaceuticals, where he initiated drug discovery efforts that led to the approval of multiple cancer treatments (renal cell, liver, and nasopharyngeal). Frank is a Fellow of the Royal Society (FRS) and member of the National Academies of Science.

  • Photo: Daniel Portnoy

    Daniel Portnoy

    Advisor

    Ph. D.

    Daniel is a Distinguished Chair in Global Public Health and Infectious Diseases and Professor of Biochemistry, Biophysics and Structural Biology at the University of California Berkeley. He is a member of the National Academies of Science, an NIH Merit Award recipient, and serves on the advisory board of Aduro Biotech, a clinical-stage cancer immunotherapy company.

  • Photo: Vahe Bedian

    Vahe Bedian

    Advisor

    Ph.D.

    Vahe is retired from a career in cancer pharmaceutical R&D, biotherapeutics, and immuno-oncology. He is currently serving as a consultant and advisor to biotechs and non-profits.

  • Photo: Tom Dubensky

    Tom Dubensky

    Advisor

    Ph.D.

    Tom is the President and CEO of ImmuneSensor Therapeutics. Previously he served as the President of Tempest Therapeutics and the CSO at Aduro, Immune Design, and Anza.

  • Photo: Steve Abella

    Steve Abella

    Advisor

    M.D.

    Steve has been in the oncology clinical research field for 35 years, including over 12 years in the pharmaceutical industry. Steve is the Chief Medical Officer (CMO) of Shasqi, and previously held roles as the CMO at Vida Development Sciences and BioClin Therapeutics. He also previously served as Executive Director at Amgen, where he led global development efforts across clinical research and medical affairs.

  • Photo: Erika Pearce

    Erika Pearce

    Advisor

    Ph.D.

    Dr. Pearce is an expert and leader in the field of immunology research and Johns Hopkins Bloomberg Distinguished Professor whose research focuses on the impact that immune cell metabolism has on immunity, infection, and cancer.

  • Photo: Ed Pearce

    Ed Pearce

    Advisor

    Ph.D

    Dr. Pearce is an immunobiology expert and Johns Hopkins Bloomberg Distinguished Professor whose research focuses on investigating immune cell metabolic reprogramming and type 2 immune responses.

  • Photo: Ronald Parchem

    Ronald Parchem

    Advisor

    Ph.D.

    Ron is a professor in Baylor's Department of Neuroscience at the Stem Cells and Regenerative Medicine Center, where his research focuses on neural development, stem cells, and cancer biology. He received his Ph.D. from U.C. Berkeley and did his post-doctoral fellowship at U.C. San Francisco.